New strategies in the treatment of the thalassemias

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 157-171

  Schrier, Stanley L ^a   Angelucci, Emanuele ^b  

^a STANFORD UNIVERSITY   (United States)

^b Ospedale Oncologico A Businco   (Italy)

Author keywords

Gene therapy; Heart disease; Iron chelation; Iron overload; Stem cell transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ARGININE BUTYRATE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; ERYTHROPOIETIN; HEMOGLOBIN F; HEMOGLOBIN H; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; REACTIVE OXYGEN METABOLITE; SILDENAFIL; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ALPHA THALASSEMIA; ARTHRALGIA; BETA THALASSEMIA; BONE MARROW SUPPRESSION; DRUG CHOICE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; IRON OVERLOAD; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLENECTOMY; SYSTEMATIC REVIEW; THALASSEMIA;

ALPHA-THALASSEMIA; ANEMIA, HEMOLYTIC, CONGENITAL; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; ERYTHROCYTE TRANSFUSION; GENE THERAPY; GENETIC COUNSELING; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; PRENATAL DIAGNOSIS; THALASSEMIA;

EID: 14544272861     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.082103.104718     Document Type: Review

References (37)

1. Valbonesi M, Bruni R. 2000. Clinical application of therapeutic erythrocytapheresis (TEA). Transfus. Sci. 22:183-94
2. Esposito BP, Breuer W, Sirankapracha P, et al. 2003. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:2670-77
3. Borgna-Pignatti C, Vergine G, Lombardo T, et al. 2004. Hepatocellular carcinoma in the thalassemia syndromes. Br. J. Haematol. 124:114-17
4. Wonke B. 2001. Clinical management of beta-thalassemia major. Semin. Hematol. 38(4):350-59
5. Modell B, Khan M, Darlison M. 2000. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355:2051-52
6. Anderson LJ, Wonke B, Prescott E, et al. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentration and ventricular function in betathalassemia. Lancet 360:516-20
7. Piga A, Gaglioti C, Fogliacco E, et al. 2003. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologia 88:489-96
8. 14C-deferiprone in normal, thalassemic and sickle red blood cells. Br. J. Haematol. 105:1081-83
9. Hoffbrand AV, Cohen A, Hershko C. 2003. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17-24
10. Wu KH, Chang JS, Tsai CH, Peng CT. 2003. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann. Hematol. 83(7):471-73
11. Alebouyeh M, Moussavi F, Hadded-Deylami H, et al. 2004. Hydroxyurea in the treatment of beta-thalassemia, and importance of genetic screening. Ann. Hematol. Jan. 14 Epub
12. Bradai M, Abad MT, Piussard S, et al. 2003. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 102:1529-30
13. Rodgers GP, Saunthararajah Y. 2001. Advances in experimental treatment of betathalassemia. Expert Opin. Investig. Drugs 10:925-34
14. Witt O, Monkemeyere S, Ronndahl G, et al. 2003. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-7
15. Galenello R. 2003. A thalassemic child becomes adult. Rev. Clin. Exp. Hematol. 7:4-21
16. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. 2003. Metabolic and endocrinologic complications in betathalassemia major: a multicenter study in Tehran. BMC Endocr. Disord. 12:4-8
17. Voskardou E, Terpos E, Spina G, et al. 2003. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br. J. Haematol. 123:730-37
18. Morabito M, Lasco A, Gaudio A, et al. 2002. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 13:644-49
19. Chui DHK, Waye JS. 1998. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood 91:2213-22
20. Davis BA, O'Sullivan C, Jarritt PH, et al. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood Mar. 4 Epub
21. Aessopos A, Farmakis D, Karagiorga M, et al. 2001. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97(11):3411-16
22. Eldor A, Rachmilewitz E. 2002. The hypercoagulable state in thalassemia. Blood Rev. 99(1):36-43
23. Modell B, Harris R, Lane B, et al. 2000. Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ 320(7231):337-41
24. Angelucci E, Lucarelli G. 2001. Bone marrow transplantation for thalassemia. In Disorders of Hemoglobin-Genetics, Pathophysiology, and Clinical Managements, ed. MH Steinberg, BG Forget, DR Higgs, RL Nagel, 39:1052-72. Cambridge, UK: Cambridge Univ. Press
25. Lucarelli G, Andreani M, Angelucci E. 2002. The cure of thalassemia by bone marrow transplantation. Blood Rev. 16:81-85
26. Sodani P, Gaziev J, Polchi P, et al. 2004. A new approach for bone marrow transplantation in class 3 thalassemia patients aged less than 17 years. Blood 104:1201-3
27. Locatelli F, Rocha V, Reed W, et al. 2003. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 101:2137-43
28. Fiorentino F, Biricik A, Karadayi H, et al. 2004. Development and clinical application of a strategy for preimplantation genetic diagnosis of single gene disorders combined with HLA matching. Mol. Hum. Reprod. 10:445-60
29. Verlinsky Y, Rechitsky S, Sharapova T, et al. 2004. Preimplantation HLA testing. JAMA 29:2079-85
30. Andreani M, Nesci S, Lucarelli G, et al. 2000. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25(4): 401-4
31. Angelucci E, Muretto P, Lucarelli G, et al. 1997. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 90:994-98
32. Angelucci E, Brittenham G, McLaren C, et al. 2000. Hepatic iron concentration and total body iron stores in thalassemia major. N. Engl. J. Med. 343:327-31
33. Giardini C, Galimberti M, Lucarelli G, et al. 1997. Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant. 20:767-72
34. Muretto P, Angelucci E, Lucarelli G. 2002. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann. Intern. Med. 136:667-72
35. Rivella S, May C, Chadburn A, et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101:2932-39
36. May C, Rivella S, Chadburn A, et al. 2002. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99:1902-8
37. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-Xl. Science 302(5644):415-19